PetVivo (PETV) investor relations material

Market opportunity and industry trends

• US companion animal veterinary care and product sales market valued at $39.8B, with a historical CAGR of ~6% from 2020-2024.

• Pet spending in the US rose from $152B in 2024 to $157B in 2025, with veterinary care as a key growth driver.

• 71% of US households own a pet, with increasing willingness to spend on pet health.

• Pet health insurance market is rapidly expanding, with insured pets rising from 5.17M in 2024 to 6.4M in 2025.

• Market is primed for innovative medical devices and therapeutics for companion animals.

Product innovation and pipeline

• SpryngⓇ with OsteoCushionⓇ Technology is a veterinary device designed to restore joint mechanics and manage lameness and osteoarthritis.

• Revivion™ is a next-generation platform combining collagen-elastin hydrogel microparticles with piezoelectric nanofibers for enhanced joint health.

• Product pipeline includes devices for osteoarthritis, ocular care, wound care, respiratory indications, and drug delivery for canine, equine, and feline species.

• Human product pipeline under development, requiring FDA clearance.

• No FDA review required for commercialization of veterinary medical devices.

Clinical efficacy and safety

• SpryngⓇ provides biocompatible, lubricious, and viscoelastic biomaterial, mimicking natural cartilage components.

• Case studies and clinical trials show long-lasting improvement in lameness and joint function in dogs, cats, and horses.

• Tolerance studies in dogs and cats demonstrated excellent safety profiles with no observed abnormalities.

• Peer-reviewed studies indicate SpryngⓇ reduces inflammatory responses and supports joint health.

• Over 15,000 animals have been successfully treated with SpryngⓇ.